<DOC>
	<DOCNO>NCT03046303</DOCNO>
	<brief_summary>This study prospective , single-center , randomize control trial . The study protocol approve Ethics Committee First Hospital Jilin University.ERAS combine laprascopic gastrectomy ass efficacy safety patient advance gastric carcinoma.The hospitalize patient randomly divide ERAS group conventional pathway group . Inter-group difference evaluate clinical recovery index , economic indicator , length hospital stay , 3 year 5 year long-term survival , etc .</brief_summary>
	<brief_title>Radical Gastrectomy Within Enhanced Recovery Programs ( ERAS ) : Prospective Randomized Controlled Trial</brief_title>
	<detailed_description />
	<criteria>( 1 ) A preoperative cancer stage T2 , T3 , T4 , Any N , M0 without digestive obstruction confirm whole body CT scan , could treat laparoscopic gastrectomy ; ( 2 ) age 1875 year ; ( 3 ) pathologic confirmation gastric adenocarcinoma endoscopic biopsy ; ( 4 ) normal hematological , renal , hepatic , cardiac parameter , ASA score &lt; III without severe systemic disease ; ( 5 ) history treatment neoadjuvant chemotherapy and/or radiotherapy . patient require conversion open gastrectomy ; excessive bleeding ( Ëƒ 500 mL ) ; patient opt study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ERAS , gastric cancer</keyword>
</DOC>